Atezolizumab Brand Name– Tecentriq
What is Atezolizumab
Atezolizumab is an Fc-engineered, humanized, non-glycosylated IgG1 kappa monoclonal antibody that binds to and blocks programmed death-ligand 1 (PD-L1).
It is indicated for certain types of urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, and triple-negative breast cancer.
Treatment with atezolizumab may result in severe immune-related adverse reactions requiring interruption or discontinuation of therapy, as well as treatment with high-dose corticosteroids.
Infusion-related reactions may also occur.
Indications
- bladder cancer
- breast cancer
- non-small cell lung cancer (NSCLC)
- renal cell cancer
- small cell lung cancer (SCLC)
- urothelial carcinoma
For the treatment of urothelial carcinoma, including bladder cancer and other urinary system cancers
for the treatment of locally advanced or metastatic urothelial carcinoma, including bladder cancer and other urinary system cancers, in patients who progress during or following any platinum-containing chemotherapy
Side Effects
- abdominal pain
- abdominal pain
- acneiform rash
- adrenocortical insufficiency
- adrenocortical insufficiency
- alopecia
- anemia
- anemia
- anorexia
- anorexia
- antibody formation
- arthralgia
- arthralgia
- asthenia
- asthenia
- back pain
- back pain
- bone pain
- bowel ischemia
- bullous rash
- colitis
- colitis
- confusion
- constipation
- constipation
- cough
- cough
- cystitis
- dehydration
- diabetes mellitus
- diabetic ketoacidosis
- diarrhea
- diarrhea
- dizziness
- dysesthesia
- dysgeusia
- dyspnea
- dyspnea
- edema
- elevated hepatic enzymes
- elevated hepatic enzymes
- encephalopathy
- enterocolitis
- epistaxis
- erythema multiforme
- fatigue
- fatigue
- fever
- fever
- GI obstruction
- Guillain-Barre syndrome
- headache
- hematuria
- hematuria
- hemolytic anemia
- hemoptysis
- hepatitis
- hepatitis
- hyperamylasemia
- hyperbilirubinemia
- hyperglycemia
- hyperkalemia
- hypermagnesemia
- hypermagnesemia
- hyperphosphatemia
- hypertension
- hyperthyroidism
- hypoalbuminemia
- hypoalbuminemia
- hypocalcemia
- hypoesthesia
- hypokalemia
- hypomagnesemia
- hyponatremia
- hyponatremia
- hypophosphatemia
- hypophosphatemia
- hypophysitis
- hypothyroidism
- infection
- infection
- infusion-related reactions
- infusion-related reactions
- intracranial bleeding
- iritis
- lethargy
- lethargy
- leukopenia
- lymphopenia
- lymphopenia
- maculopapular rash
- malaise
- malaise
- meningitis
- musculoskeletal pain
- myalgia
- myalgia
- myasthenia
- myocarditis
- nausea
- nausea
- nephrotic syndrome
- neutropenia
- pancreatitis
- paresis
- paresthesias
- peripheral edema
- peripheral edema
- peripheral neuropathy
- pharyngitis
- pleural effusion
- pneumonitis
- pneumonitis
- proteinuria
- pruritus
- pruritus
- psoriaform rash
- pulmonary embolism
- purpura
- rash
- rash
- renal failure (unspecified)
- rhabdomyolysis
- Stevens-Johnson syndrome
- stroke
- thrombocytopenia
- thromboembolism
- toxic epidermal necrolysis
- uveitis
- vasculitis
- Vogt-Koyanagi-Harada syndrome
- vomiting
- vomiting
Monitoring Parameters
- blood glucose
- LFTs
- pregnancy testing
- thyroid function tests (TFTs)
Contraindications
- adrenal insufficiency
- autoimmune disease
- breast-feeding
- colitis
- contraception requirements
- diabetes mellitus
- diabetic ketoacidosis
- diarrhea
- hepatic disease
- hepatitis
- hyperthyroidism
- hypophysitis
- hypopituitarism
- hypothyroidism
- immune-mediated reactions
- infection
- infertility
- infusion-related reactions
- myocarditis
- pancreatitis
- pneumonitis
- pregnancy
- pregnancy testing
- pulmonary disease
- renal impairment
- reproductive risk
- thyroid disease
- uveitis
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
Palifermin: (Moderate) Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of antineoplastic agents.
Penicillamine: (Major) Do not use penicillamine with antineoplastic agents due to the increased risk of developing severe hematologic and renal toxicity.
Tuberculin Purified Protein Derivative, PPD: (Moderate) Immunosuppressives may decrease the immunological response to tuberculin purified protein derivative, PPD. This suppressed reactivity can persist for up to 6 weeks after treatment discontinuation. Consider deferring the skin test until completion of the immunosuppressive therapy.
